{
  "docId": "019de077-0f5f-77ef-a5cf-60b15fd5a5a5",
  "docSlug": "f1a62332dbdfff6b54feb25498e49e7e",
  "documentTitle": "Matinas BioPharma | Investor Presentation Deck | 29 slides",
  "authorId": "matinas-biopharma",
  "authorName": "Matinas BioPharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 26,
  "pageCount": 29,
  "prevPage": 25,
  "nextPage": 27,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 4,
  "notes": "The slide uses a two-column layout to contrast oncology and inflammation results, followed by a summary box of platform capabilities.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de077-0f5f-77ef-a5cf-60b15fd5a5a5/26",
  "deckHref": "/decks/019de077-0f5f-77ef-a5cf-60b15fd5a5a5",
  "deckJsonHref": "/decks/019de077-0f5f-77ef-a5cf-60b15fd5a5a5.json",
  "deckAnchorHref": "/decks/019de077-0f5f-77ef-a5cf-60b15fd5a5a5#slide-26",
  "components": [
    {
      "bbox": {
        "h": 0.18,
        "w": 0.64,
        "x": 0.18,
        "y": 0.735
      },
      "kind": "callout",
      "text": "Key LNC Capabilities: Oral delivery, Delivery of active therapeutics to diseased tissues outside the liver, Low blood levels of active drug, with potential for improved safety",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "00c1aceb-8321-42bf-855c-dbdee0c44dec",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.45,
        "x": 0.52,
        "y": 0.18
      },
      "kind": "list",
      "text": "Inflammation: Successful in vivo oral LNC delivery of 2 different RNAi oligonucleotides; Documented biological activity in Psoriasis and Colitis models.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5e4d2e59-006c-4161-af5b-5aa52eef0bdc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.45,
        "x": 0.05,
        "y": 0.18
      },
      "kind": "list",
      "text": "Oncology: Successful in vivo oral delivery of LNC-docetaxel in a melanoma tumor model; Reductions in tumor weight and volume; Corroboration of safety in healthy mice with higher doses.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "aa1c3c5c-1b41-4cee-9103-291eae7884af",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Recent Key Advances Highlight Broader Applicability of LNC Platform Capabilities",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6ea1a49b-2a38-48c1-b81e-7cb803f478db",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "d26ed6de-791a-475a-ab38-c69bedc5d2e1",
      "evidence": "The slide features a list of bullet points highlighting key capabilities and results, making it easy to quickly scan and understand the information.",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 29,
      "from": 15,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "c020a8cd-19c2-4f66-b8fd-1a6de00826c3",
      "evidence": "The regulatory and development strategy for MAT2203 and the LNC platform are presented",
      "position": 2,
      "objective": "What are the near-term milestones and potential for growth?",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.6,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}